Iovance Biotherapeutics Inc. News
Biotech Stocks Are Cheap. Is It Time for Blockbuster M&A?
Valuations for biotech stocks have slumped. This in particular opens up great opportunities for mergers and acquisitions.
Iovance Drops After Update on Lung Cancer Treatment Study
Shares of Iovance Biotherapeutics dropped after the cancer-drug developer updated investors on its experimental lung cancer treatment.
5 Top Stock Gainers for Thursday: Iovance, Virgin Galactic
Iovance Biotherapeutics, Shoals Technologies, Virgin Galactic, Hormel Foods and Chipotle Mexican Grill are five top stock gainers for Thursday.
Iovance Tumbles on Drug Application Delay, CEO Resignation
Iovance shares plummet after the company announces a delay in its FDA application for an experimental treatment and its CEO resigns.
Iovance Shares Tumble After Delaying FDA Cancer Drug Application
Iovance said late Monday that it won't make a Biologics License Application with the FDA for its key skin cancer drug, lifileucel, until next year.
Amarin Shares Crushed After Judge Rules Heart Drug Patents Invalid: Report
Pharmaceutical maker Amarin sees shares lose more than half their value in late trading following adverse ruling in federal court.
Stay on Top of Your Game: Cramer's 'Mad Money' Recap
Jim Cramer says investors need to stay vigilant, despite recent market gains. He's got your game plan for next week.
Magellan Midstream, Xylem, Boston Scientific: 'Mad Money' Lightning Round
Jim Cramer takes a closer look at Magellan Midstream Partners, Xylem, Boston Scientific, Karyopharm Thereapeutics, Iovance Biotherapeutics, Casella Waste Systems and more.
Cisco Systems Stock Leaps On Q4 Earnings Beat, 2023 Sales Outlook As Supply Chain Pressures Ease
"Overall supply constraints began to ease slightly at the back half of the fourth quarter and continuing into the start of the first quarter," said CEO Chuck Robbins.
Ransomware Suspect Charged in U.S. as Incidents Surge
A Russian citizen is charged in the U.S. for his alleged role in an international cryptocurrency money laundering conspiracy.
TheStreet's Doug Kass: Don't Be Fooled by Stock Rally
The S&P 500 index has jumped 11% in the past month, 'reducing the general attraction of equities,' investor Doug Kass says.